OvaScience Announces Pricing of Public Offering of Common Stock
WALTHAM, Mass.–(BUSINESS WIRE)–OvaScienceSM (NASDAQ: OVAS), a global fertility company
focused on the discovery, development and commercialization of new
treatment options, announced today that it has priced its previously
announced underwritten public offering of 7,150,000 shares of its common
stock at a public offering price of $7.00 per share. Net proceeds to
OvaScience from this offering are expected to be approximately $46.8
million, after deducting underwriting discounts and commissions and
estimated offering expenses. OvaScience intends to use the proceeds from
this offering to fund the commercial expansion of the AUGMENTSM
treatment in its key regions, Japan and Canada, the ongoing
pre-commercial activities for the OvaPrimeSM treatment and
the OvaTureSM treatment, and working capital and other
general corporate purposes.
OvaScience has granted the underwriters a 30-day option to purchase up
to an additional 1,072,500 shares of common stock offered in the public
offering. All of the shares in the offering will be sold by OvaScience.
The offering is expected to close on June 1, 2016, subject to customary
closing conditions. Leerink Partners LLC is acting as sole book runner
for the offering. Oppenheimer & Co. Inc., H. C. Wainwright & Co., Roth
Capital Partners, LLC and JonesTrading Institutional Services LLC are
acting as co-managers for the offering.
The public offering is being made pursuant to a shelf registration
statement on Form S-3 that was previously filed with and declared
effective by the Securities and Exchange Commission (“SEC”). A
preliminary prospectus supplement and accompanying base prospectus
relating to and describing the terms of the offering has been filed with
the SEC and is available on the SEC’s website at www.sec.gov.
A final prospectus relating to the offering will be filed with the SEC.
Copies of the final prospectus and accompanying prospectus relating to
the offering, when available, may be obtained from Leerink Partners LLC;
Attention: Syndicate Department; One Federal Street; 37th Floor; Boston,
MA, 02110, or by phone at 1-800-808-7525, ext. 6142, or by email at syndicate@leerink.com.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy, nor shall there be any sale of these
securities in any state or jurisdiction in which such an offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
About OvaScience
OvaScience, Inc. (NASDAQ: OVAS) is a global fertility company dedicated
to improving treatment options for women around the world. OvaScience is
discovering, developing and commercializing new fertility treatments
because it believes women deserve more options. Each OvaScience
treatment is based on the Company’s proprietary technology platform that
leverages the breakthrough discovery of egg precursor (EggPCSM)
cells – immature egg cells found inside the protective ovarian lining.
The AUGMENTSM treatment, a fertility option specifically
designed to improve egg health, is available in certain IVF clinics in
select international regions. OvaScience has commenced a non-commercial
preceptorship training program with the OvaPrimeSM treatment,
which could increase a woman’s egg reserve, and is developing the OvaTureSM treatment,
a potential next-generation IVF treatment that could help a woman
produce healthy, young, fertilizable eggs without hormone injections.
OvaScience treatments are not available in the U.S.
Forward-Looking Statements
This press release includes forward-looking statements including
statements about OvaScience’s proposed public offering of securities and
the intended use of proceeds therefrom. Actual results may differ
materially from those indicated by these forward-looking statements as a
result of various important factors, including risks related to: the
possibility that international IVF clinics that OvaScience works with
may determine not to provide or continue providing or studying the
AUGMENT treatment or OvaPrime treatment, or to delay providing such
treatments, based on clinical efficacy, safety or commercial, logistic,
regulatory, enrollment, inability to agree on commercial terms, or other
reasons; the science underlying the company’s treatments (including the
AUGMENT, OvaPrime and OvaTure treatments), which is unproven; the
Company’s ability to obtain regulatory approval or licenses where
necessary for its treatments; OvaScience’s ability to develop its
treatments on the timelines it expects, if at all; the Company’s ability
to commercialize its treatments, on the timelines it expects, if at all;
as well as those risks more fully discussed in the “Risk Factors”
section of its most recently filed Annual Report on Form 10-K and
Quarterly Reports on Form 10-Q. The forward-looking statements contained
in this press release reflect the Company’s current views with respect
to future events. It anticipates that subsequent events and developments
will cause its views to change. However, while it may elect to update
these forward-looking statements in the future, it specifically
disclaims any obligation to do so. These forward-looking statements
should not be relied upon as representing OvaScience’s view as of any
date subsequent to the date hereof.
## ## ##
Contacts
Media and Investor Contact:
OvaScience
Rebecca
J. Peterson, 617-420-8736
rpeterson@ovascience.com
